Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant tumor that may not only contain rhabdoid tumor cells but also poorly differentiated small‐round‐blue cells as well as areas with mesenchymal or epithelial differentiation. Little is known on factors associated with histopathological diversity. Recent studies demonstrated three molecular subgroups of AT/RT, namely ATRT‐TYR, ATRT‐SHH, and ATRT‐MYC. We thus aimed to investigate if morphological patterns might be related to molecular subgroup status. Hematoxylin‐eosin stained sections of 114 AT/RT with known molecular subgroup status were digitalized and independently categorized by nine blinded observers into four morphological categories, that is, “rhabdoid,” “small‐round‐blue,” “epithelial,” and “mesenchymal.” The series comprised 48 ATRT‐SHH, 40 ATRT‐TYR, and 26 ATRT‐MYC tumors. Inter‐observer agreement was moderate but significant (Fleiss’ kappa = 0.47; 95% C.I. 0.41‐0.53; p < 0.001) and there was a highly significant overall association between morphological categories and molecular subgroups for each of the nine observers (p < 0.0001). Specifically, the category “epithelial” was found to be over‐represented in ATRT‐TYR (p < 0.000001) and the category “small‐round‐blue” to be over‐represented in ATRT‐SHH (p < 0.01). The majority of ATRT‐MYC was categorized as “mesenchymal” or “rhabdoid,” but this association was less compelling. The specificity of the category “epithelial” for ATRT‐TYR was highest and accounted for 97% (range: 88‐99%) whereas sensitivity was low [49% (range: 35%–63%)]. In line with these findings, cytokeratin‐positivity was highly overrepresented in ATRT‐TYR. In conclusion, morphological features of AT/RT might reflect molecular alterations and may also provide a first hint on molecular subgroup status, which will need to be confirmed by DNA methylation profiling.

[1]  T. Gupta,et al.  Atypical Teratoid/Rhabdoid Tumor: Revisiting Histomorphology and Immunohistochemistry With Analysis of Cyclin D1 Overexpression and MYC Amplification , 2020, International journal of surgical pathology.

[2]  Ugljesa Djuric,et al.  Unsupervised Machine Learning in Pathology: The Next Frontier. , 2020, Surgical pathology clinics.

[3]  A. Huang,et al.  Advancing biology based therapeutic approaches for atypical teratoid rhabdoid tumors. , 2020, Neuro-oncology.

[4]  P. Northcott,et al.  SWI/SNF complex heterogeneity relates with polyphenotypic differentiation, prognosis and immune response in rhabdoid tumors. , 2019, Neuro-oncology.

[5]  M. Kool,et al.  Tyrosinase immunohistochemistry can be employed for the diagnosis of atypical teratoid/rhabdoid tumours of the tyrosinase subgroup (ATRT‐TYR) , 2020, Neuropathology and applied neurobiology.

[6]  M. Kool,et al.  Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus , 2019, Neuro-oncology.

[7]  S. Bens,et al.  Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors (ATRT). , 2019, Neuro-oncology.

[8]  Steven J. M. Jones,et al.  Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration , 2019, Cell reports.

[9]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[10]  David T. W. Jones,et al.  Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1‐deficient non‐rhabdoid tumor with favorable long‐term outcome , 2017, Brain pathology.

[11]  Jie Ma,et al.  Atypical teratoid/rhabdoid tumours: clinicopathological characteristics, prognostic factors and outcomes of 22 children from 2010 to 2015 in China. , 2016, Pathology.

[12]  Mei Lu,et al.  Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. , 2016, Cancer cell.

[13]  C. Roberts,et al.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. , 2016, Neuro-oncology.

[14]  Roland Eils,et al.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.

[15]  M. Al-Hussaini,et al.  Atypical teratoid/ rhabdoid tumor, an immunohistochemical study of potential diagnostic and prognostic markers , 2016, Neuropathology : official journal of the Japanese Society of Neuropathology.

[16]  M. Bronner,et al.  Establishing neural crest identity: a gene regulatory recipe , 2015, Development.

[17]  Chris Allan,et al.  OME Remote Objects (OMERO): a flexible, model-driven data management system for experimental biology , 2012, Nature Methods.

[18]  R. Siebert,et al.  Cribriform Neuroepithelial Tumor (CRINET): A Nonrhabdoid Ventricular Tumor With INI1 Loss and Relatively Favorable Prognosis , 2009, Journal of neuropathology and experimental neurology.

[19]  T. Shaikh,et al.  Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors , 2009, Clinical Cancer Research.

[20]  H. Budka,et al.  Immunohistochemical Analysis of INI1 Protein in Malignant Pediatric CNS Tumors: Lack of INI1 in Atypical Teratoid/Rhabdoid Tumors and in a Fraction of Primitive Neuroectodermal Tumors without Rhabdoid Phenotype , 2006, The American journal of surgical pathology.

[21]  M. Rosenblum,et al.  INI1 Protein Expression Distinguishes Atypical Teratoid/Rhabdoid Tumor from Choroid Plexus Carcinoma , 2005, Journal of neuropathology and experimental neurology.

[22]  J. Biegel,et al.  Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood , 2005, Journal of Neuro-Oncology.

[23]  J. Biegel,et al.  Immunohistochemical Analysis of hSNF5/INI1 in Pediatric CNS Neoplasms , 2004, The American journal of surgical pathology.

[24]  J. Biegel,et al.  Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. , 1999, Cancer research.

[25]  J. Biegel,et al.  Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. , 1996, Journal of neurosurgery.

[26]  D. Parham,et al.  The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy. , 1994, The American journal of surgical pathology.

[27]  J. Beckwith,et al.  Rhabdoid tumor. An entity or a phenotype? , 1989, Archives of pathology & laboratory medicine.